Network and systems biology: essential steps in virtualising drug discovery and development.
暂无分享,去创建一个
Hans Lehrach | Christoph Wierling | Thomas Kessler | Marie-Laure Yaspo | Lesley A Ogilvie | H. Lehrach | M. Yaspo | C. Wierling | T. Kessler | B. Lange | L. Ogilvie | Bodo M H Lange
[1] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[2] M Heath-Chiozzi,et al. Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.
[3] O Mason,et al. Graph theory and networks in Biology. , 2006, IET systems biology.
[4] R. Iyengar. Complex diseases require complex therapies , 2013, EMBO reports.
[5] Ralf Herwig,et al. ConsensusPathDB: toward a more complete picture of cell biology , 2010, Nucleic Acids Res..
[6] M. Dunning,et al. Genome-driven integrated classification of breast cancer validated in over 7,500 samples , 2014, Genome Biology.
[7] Ralf Herwig,et al. ConsensusPathDB—a database for integrating human functional interaction networks , 2008, Nucleic Acids Res..
[8] David M. Wilson,et al. Network biology as a new approach to drug discovery. , 2010, Current opinion in drug discovery & development.
[9] Mark A. Murcko,et al. Virtual screening : an overview , 1998 .
[10] Ulrich Keilholz,et al. Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack , 2014, Biotechnology journal.
[11] Albert-László Barabási,et al. Observability of complex systems , 2013, Proceedings of the National Academy of Sciences.
[12] T. Ideker,et al. Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.
[13] F. Bertucci,et al. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. , 2014, Cancer letters.
[14] C. Cobelli,et al. In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes , 2009, Journal of diabetes science and technology.
[15] Bertram Klinger,et al. Supplementary Materials for : Network quantification of EGFR signaling unveils potential for targeted combination therapy , 2022 .
[16] H. Lehrach. DNA sequencing methods in human genetics and disease research , 2013, F1000prime reports.
[17] L. Hutchinson,et al. High drug attrition rates—where are we going wrong? , 2011, Nature Reviews Clinical Oncology.
[18] Jens Timmer,et al. Systems-level interactions between insulin–EGF networks amplify mitogenic signaling , 2009, Molecular systems biology.
[19] H. Lehrach,et al. IT Future of Medicine: from molecular analysis to clinical diagnosis and improved treatment. , 2013, New biotechnology.
[20] David R. Gilbert,et al. Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway , 2009, BMC Systems Biology.
[21] Jeffrey R. Whiteaker,et al. Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.
[22] H. Lehrach,et al. Resources, standards and tools for systems biology. , 2007, Briefings in functional genomics & proteomics.
[23] Nathan D. Price,et al. Demystifying Disease, Democratizing Health Care , 2014, Science Translational Medicine.
[24] Hans Lehrach,et al. Future of medicine: models in predictive diagnostics and personalized medicine. , 2013, Advances in biochemical engineering/biotechnology.
[25] Andriani Daskalaki,et al. High-Throughput miRNA and mRNA Sequencing of Paired Colorectal Normal, Tumor and Metastasis Tissues and Bioinformatic Modeling of miRNA-1 Therapeutic Applications , 2013, PloS one.
[26] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[27] Jeffrey T. Chang,et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.
[28] N. Kikuchi,et al. CellDesigner 3.5: A Versatile Modeling Tool for Biochemical Networks , 2008, Proceedings of the IEEE.
[29] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[30] Anne Mai Wassermann,et al. Bioturbo Similarity Searching: Combining Chemical and Biological Similarity To Discover Structurally Diverse Bioactive Molecules , 2013, J. Chem. Inf. Model..
[31] A. Y. Lu,et al. Pharmacogenetics, Pharmacogenomics, and Individualized Medicine , 2011, Pharmacological Reviews.
[32] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[33] Hugo Y. K. Lam,et al. Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.
[34] A. Barabasi,et al. Systems biology and the future of medicine , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.
[35] Xiang-Dong Fu,et al. Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery , 2012, Proceedings of the National Academy of Sciences.
[36] M. Ramanathan,et al. Network‐Based Approaches in Drug Discovery and Early Development , 2013, Clinical pharmacology and therapeutics.
[37] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[38] Brad T. Sherman,et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.
[39] Barbara M. Bakker,et al. Emergence of the silicon human and network targeting drugs. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[40] Andriani Daskalaki,et al. Prediction in the face of uncertainty: a Monte Carlo-based approach for systems biology of cancer treatment. , 2012, Mutation research.
[41] Reinhard Schneider,et al. Using graph theory to analyze biological networks , 2011, BioData Mining.
[42] Eytan Domany,et al. Outcome signature genes in breast cancer: is there a unique set? , 2004, Breast Cancer Research.
[43] Jérôme Hert,et al. New Methods for Ligand-Based Virtual Screening: Use of Data Fusion and Machine Learning to Enhance the Effectiveness of Similarity Searching , 2006, J. Chem. Inf. Model..
[44] J. V. Moran,et al. Initial sequencing and analysis of the human genome. , 2001, Nature.
[45] W. Gradishar,et al. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. , 2012, Journal of the National Cancer Institute.
[46] T. Fan,et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. , 2012, Cell metabolism.
[47] Dipak Barua,et al. Modeling the Effect of APC Truncation on Destruction Complex Function in Colorectal Cancer Cells , 2013, PLoS Comput. Biol..
[48] Gary D Bader,et al. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα− breast cancer , 2012, Proceedings of the National Academy of Sciences.
[49] Zachary A. King,et al. Constraint-based models predict metabolic and associated cellular functions , 2014, Nature Reviews Genetics.
[50] Sabine Tejpar,et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer , 2013, The Journal of pathology.
[51] Rudi Balling,et al. Revolutionizing medicine in the 21st century through systems approaches. , 2012, Biotechnology journal.
[52] Daniel C Kirouac,et al. Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors , 2013, Science Signaling.
[53] Ruth Nussinov,et al. Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.
[54] Michael R. Green,et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. , 2012, Cancer cell.
[55] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[56] C. Sander,et al. Integrative Subtype Discovery in Glioblastoma Using iCluster , 2012, PloS one.
[57] Mudita Singhal,et al. COPASI - a COmplex PAthway SImulator , 2006, Bioinform..
[58] Ronan M. T. Fleming,et al. A community-driven global reconstruction of human metabolism , 2013, Nature Biotechnology.
[59] Costas Kravaris,et al. Advances and selected recent developments in state and parameter estimation , 2013, Comput. Chem. Eng..
[60] Corbin E. Meacham,et al. Tumour heterogeneity and cancer cell plasticity , 2013, Nature.
[61] S. Huang,et al. Genomics, complexity and drug discovery: insights from Boolean network models of cellular regulation. , 2001, Pharmacogenomics.
[62] Gary D. Bader,et al. Pathway Commons, a web resource for biological pathway data , 2010, Nucleic Acids Res..
[63] B. Al-Lazikani,et al. Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.
[64] M. Abba,et al. Breast Cancer Biomarker Discovery in the Functional Genomic Age: A Systematic Review of 42 Gene Expression Signatures , 2010, Biomarker insights.
[65] A. Sarai,et al. Genetic algorithm optimization in drug design QSAR: Bayesian-regularized genetic neural networks (BRGNN) and genetic algorithm-optimized support vectors machines (GA-SVM) , 2011, Molecular Diversity.
[66] H. Lehrach,et al. The “Virtual Patient” system: modeling cancer using deep sequencing technologies for personalized cancer treatment , 2012, Journal für Verbraucherschutz und Lebensmittelsicherheit.
[67] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[68] Gary D Bader,et al. International network of cancer genome projects , 2010, Nature.
[69] S. Friend,et al. A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.